Becton Dickinson and Company
$ 165.62
0.10%
31 Jul - close price
- Market Cap 45,635,002,000 USD
- Current Price $ 165.62
- High / Low $ 166.29 / 162.45
- Stock P/E 28.90
- Book Value 87.58
- EPS 5.73
- Next Earning Report 2026-08-06
- Dividend Per Share $4.18
- Dividend Yield 2.53 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.07 %
- 52 Week High 184.86
- 52 Week Low 125.21
About
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Analyst Target Price
$180.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-09 | 2025-11-06 | 2025-08-07 | 2025-05-01 | 2025-02-05 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-01 | 2023-11-09 | 2023-08-03 |
| Reported EPS | 2.9 | 2.91 | 3.96 | 3.68 | 3.35 | 3.43 | 3.81 | 3.5 | 3.17 | 2.68 | 3.42 | 2.96 |
| Estimated EPS | 2.77 | 2.8 | 3.91 | 3.42 | 3.28 | 2.99 | 3.77 | 3.31 | 2.97 | 2.4 | 3.43 | 2.91 |
| Surprise | 0.13 | 0.11 | 0.05 | 0.26 | 0.07 | 0.44 | 0.04 | 0.19 | 0.2 | 0.28 | -0.01 | 0.05 |
| Surprise Percentage | 4.6931% | 3.9286% | 1.2788% | 7.6023% | 2.1341% | 14.7157% | 1.061% | 5.7402% | 6.734% | 11.6667% | -0.2915% | 1.7182% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 3.14 |
| Currency | USD |
Previous Dividend Records
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-28 |
| Amount | $1.05 | $1.05 | $1.05 | $1.05 | $1.04 | $1.04 | $1.04 | $1.04 | $0.95 | $0.95 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDX
2026-08-02 06:21:19
BD (Becton, Dickinson and Company) has partnered with EMS to launch a semaglutide therapy in Brazil using BD’s Vystra Injection Pen platform, catering to the growing demand for injectable GLP-1 therapies. This collaboration highlights BD’s drug delivery expertise and its potential long-term growth driver in the emerging healthcare market, while the company continues to manage ongoing operational risks and maintains its dividend. Investors are encouraged to assess how this partnership fits into BD's broader investment narrative and financial forecasts.
2026-08-02 05:37:19
BD (Becton, Dickinson and Company) has partnered with EMS to launch a semaglutide therapy in Brazil using BD's Vystra Injection Pen, aiming to address the rising demand for GLP-1 therapies in chronic conditions like obesity and type 2 diabetes. This collaboration is seen as a key long-term growth driver, complementing BD's existing focus on recurring revenue from medical consumables and drug delivery, despite facing ongoing execution risks related to its Biosciences/Diagnostics separation and regulatory complexities. The article suggests this move could strengthen BD's investment narrative, with analysts forecasting revenue and earnings growth by 2029.
2026-08-01 15:09:10
Axogen, Inc. (NASDAQ:AXGN) saw its shares rise 6.9% after its second-quarter results, which showed revenues slightly ahead of estimates at US$70m, though statutory losses were 5.0% larger than predicted. Analysts have since updated their forecasts, now predicting 2026 revenues of US$279.5m (an 11% improvement) and a substantial reduction in losses to US$0.46 per share, despite a notable increase in per-share loss estimates. While the consensus price target remained steady at US$53.22, suggesting growing revenues are offsetting concerns about increased losses, the company's expected growth rate is significantly faster than its industry peers.
2026-08-01 06:37:00
This article details the career and leadership of Robert B. Ford, Chairman and CEO of Abbott Laboratories. It highlights his unique background, including a Boston College communications degree and a Haas MBA, his early career in Brazil, and his ascent through Abbott's ranks. The article emphasizes his significant contributions during the COVID-19 pandemic and his strategic vision for connected health technologies, such as the FreeStyle Libre.
2026-07-30 16:51:00
Becton Dickinson & Co. (BDX) stock fell 1.75% on Thursday, closing at $165.45, despite an overall positive trading session for the broader market. This drop snapped a four-day winning streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average both saw gains on the same day.
2026-07-30 01:37:37
Danaher Corp. (DHR) had approximately 60,225 employees worldwide as of March 2026, representing a 0.8% decline from 2023. The company is actively hiring, with 6,341 active job postings in 2026, a 14.2% increase from 2025. Danaher's workforce is concentrated in the United States, India, and the United Kingdom, with a global average salary of $82,291.
